Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Non-Current Liabilities (2021 - 2025)

Indivior Pharmaceuticals has reported Total Non-Current Liabilities over the past 5 years, most recently at $1.3 billion for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $1.3 billion for Q4 2025, down 21.73% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (down 21.73% YoY), and the annual figure for FY2025 was $1.3 billion, down 21.73%.
  • Total Non-Current Liabilities for Q4 2025 was $1.3 billion at Indivior Pharmaceuticals, down from $1.6 billion in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for INDV hit a ceiling of $1.7 billion in Q2 2025 and a floor of $649.0 million in Q4 2023.
  • Median Total Non-Current Liabilities over the past 5 years was $1.4 billion (2025), compared with a mean of $1.3 billion.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 151.77% in 2024 and later dropped 21.73% in 2025.
  • Indivior Pharmaceuticals' Total Non-Current Liabilities stood at $825.0 million in 2021, then dropped by 15.27% to $699.0 million in 2022, then decreased by 7.15% to $649.0 million in 2023, then soared by 151.77% to $1.6 billion in 2024, then dropped by 21.73% to $1.3 billion in 2025.
  • The last three reported values for Total Non-Current Liabilities were $1.3 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.7 billion (Q2 2025) per Business Quant data.